Methods of treating a tumor that expresses APRIL by administering BCMA
View Patent ↗A novel receptor in the TNF family is provided: APRIL-R. Chimeric molecules and antibodies to APRIL-R and methods of use thereof are also provided.
1. A method of treating a mammal for a tumor that expresses A Proliferation Inducing Ligand (APRIL), said method comprising administering to the mammal a therapeutically effective amount of a polypeptide capable of binding to APRIL, wherein the polypeptide comprises at least one of the following amino acid sequences:
(a) an amino acid sequence which is at least 95% identical to amino acids 8 to 41 of SEQ ID NO:8; and
(b) an amino acid sequence which is at least 95% identical to amino acids 1 to 52 of SEQ ID NO:8.
2. The method of claim 1 , wherein the polypeptide comprises amino acids 8 to 41 of SEQ ID NO:8.
3. The method of claim 1 , wherein the polypeptide further comprises a signal sequence of a secreted protein.
4. The method of claim 1 , wherein the polypeptide further comprises an Fc domain of an immunoglobulin.
5. The method of claim 4 , wherein the immunoglobulin is lgG.
6. The method of claim 5 , wherein the immunoglobulin is human.
7. The method of claim 6 , wherein the polypeptide comprises amino acids 24-302 of SEQ ID NO:12.
8. The method of any one of claims 1 - 7 , wherein the mammal is a human.
9. The method of any one of claims 1 - 7 , wherein the tumor is a carcinoma.
10. The method of claim 9 , wherein the mammal is a human.
11. The method of claim 9 , wherein the carcinoma is selected from the group consisting of lung carcinoma, colon carcinoma, prostate carcinoma, and breast carcinoma.
12. The method of claim 11 , wherein the mammal is a human.
13. A method of inhibiting the activity of A Proliferation Inducing Ligand (APRIL) in a mammal having a tumor that expresses APRIL, said method comprising administering to the mammal an effective amount of a polypeptide capable of binding to APRIL, wherein the polypeptide comprises at least one of the following amino acid sequences:
(a) an amino acid sequence which is at least 95% identical to amino acids 8 to 41 of SEQ ID NO:8; and
(b) an amino acid sequence which is at least 95% identical to amino acids 1 to 52 of SEQ ID NO:8.
14. The method of claim 13 , wherein the polypeptide comprises amino acids 8 to 41 of SEQ ID NO:8.
15. The method of claim 13 , wherein the polypeptide further comprises a signal sequence of a secreted protein.
16. The method of claim 13 , wherein the polypeptide further comprises an Fc domain of an immunoglobulin.
17. The method of claim 16 , wherein the immunoglobulin is lgG.
18. The method of claim 17 , wherein the immunoglobulin is human.
19. The method of claim 18 , wherein the polypeptide comprises amino acids 24-302 of SEQ ID NO:12.
20. The method of any one of claims 13 - 19 , wherein the mammal is a human.
21. The method of any one of claims 13 - 19 , wherein the tumor is a carcinoma.
22. The method of claim 21 , wherein the mammal is a human.
23. The method of claim 21 , wherein the carcinoma is selected from the group consisting of lung carcinoma, colon carcinoma, prostate carcinoma, and breast carcinoma.
24. The method of claim 23 , wherein the mammal is a human.